Compare Adaptive Biotechnologies Corp (ADPT) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs DigitalOcean Holdings Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while DigitalOcean Holdings Inc trades at $138.54 (market cap $14.30B). The key difference: DigitalOcean Holdings Inc is far larger — about 4.3× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | DOCN | |
|---|---|---|
Market Cap | $3.33B | $14.30B |
Sector | Health | Technology |
52-Week High | $22.37 | $181.29 |
52-Week Low | $10.24 | $25.74 |
Enterprise Value | $3.19B | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DigitalOcean (DOCN) trades at $137.12, up 5.37% today amid strong Q2 2026 preliminary results showing accelerated growth. The stock exhibits bearish technical signals but maintains robust fundamentals with consistent earnings beats, 58.49% gross margins, and 24.97% net income margins. Recent news highlights inclusion in the Russell 1000 Index and AI-driven cloud demand, with analyst consensus bullish at a $169.91 price target.
Outlook remains positive given AI-native cloud positioning and revenue growth, though high valuation ratios (P/E 57.62) and negative shareholder equity pose risks. Upside depends on execution of growth initiatives, while competition and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
